Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Closes $130M Notes Offering

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market Monday that it has completed the private placement of $130 million of 5 percent convertible senior notes due 2017.

The San Diego-based molecular diagnostics firm said the placement included $20 million aggregate principal amount of notes from the full exercise of the over-allotment option.

Net proceeds from the offering will be used to fund further commercialization of Sequenom's MaterniT21 Plus non-invasive test for trisomies, 21, 18, and 13.

The notes placement follows a public offering of Sequenom common stock earlier this year that brought in $62 million in gross proceeds.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.